Abstract:Aleksey Chauin 1, 2 1 Department of Cardiology and Cardiovascular Surgery, Samara State Medical University, Samara, 443099, Russia; 2 Department of Histology and Embryology, Samara State Medical University, Samara, 443099, Russia Correspondence: Aleksey Chauin Department of Cardiology and Cardiovascular Surgery, Department of Histology and Embryology Samara State Medical University, 89 Chapaevskaya Street, Samara Region, Samara, 443099, Russia Tel +7 927 770-25-87 Email The causes and mechanisms of increased cardiac troponin T and I (cTnT and cTnI) concentrations are numerous and are not limited to acute myocardial infarction (AMI) (ischemic necrosis of cardiac myocytes). Any type of reversible or irreversible cardiomyocyte injury can result in elevated serum cTnT and cTnI levels. Researchers and practitioners involved in the diagnosis and treatment of cardiovascular disease, including AMI, should know the key causes and mechanisms of elevated serum cTnT and cTnI levels. This will allow to reduce or completely avoid diagnostic errors and help to choose the most correct tactics for further patient management. The purpose of this article is to discuss the main causes and mechanisms of increase in cardiac troponins concentrations in frequently occurring physiological (physical exertion, psycho-emotional stress) and pathological conditions (inflammatory heart disease, pulmonary embolism, chronic renal failure and sepsis (systemic inflammatory response)) not related to myocardial infarction. Keywords: diagnostics, differential diagnosis, causes of increased concentration, mechanisms of increase, cardiac troponins, troponin T, troponin I, acute myocardial infarction, physical activity, psycho-emotional stress, myocarditis, endocarditis, pericarditis, sepsis, pulmonary embolism, chronic renal failure Cardiac troponin T and I isoforms (cTnT and cTnI) are expressed in cardiac muscle tissue and are by far the most specific and sensitive indicators for the diagnosis of acute myocardial infarction (AMI). 1–4 There are only a few studies that have reported the expression of cTnT and cTnI outside the myocardium, particularly in skeletal muscle, 5–7 but the results of these studies are contradictory and have not been confirmed in other research studies. 8,9 Methods for determining cTnT and cTnI, which were first developed in the late 90s of the 20th century, 10,11 have been continuously improved, increasing analytical sensitivity and specificity. This allowed to accelerate the early diagnosis of AMI and reduce the number of false-positive results due to the interaction of anti-cTnT and anti-cTnI antibodies with skeletal troponins released from muscle fibers in skeletal myopathies and rhabdomyolysis. 12–14 Nowadays, there are highly sensitive immunoassays available for determining the hs-cTnT and hs-cTnI concentrations; they allow detecting very low (at the level of several ng/L), but diagnostically significant concentrations of cardiac troponin molecules in blood serum. 15,16 This has significantly accelerated the diagnosis of AMI, making it possible to speed up the decision-making on the choice of optimal management tactics for patients arriving with chest pain. For instance, the official edition of the Fourth Universal Definition of Myocardial Infarction (2018) regulates the use of hs-cTnT and hs-cTnI in 1h and 3h diagnostic algorithms. 1 Despite the high specificity of cTnT and cTnI, they are not ideal biomarkers for the diagnosis of AMI, since they elevate in blood serum not only in ischemic necrosis of myocardial cells, but also in a number of other pathologies that lead to damage or death of myocardial cells caused by non-ischemic factors. 17–19 Also, the improvement in analytical sensitivity of methods for determining cardiac troponins has led to a decrease in specificity, which is expressed by more frequent cases of elevated troponin levels in the absence of myocardial infarction. 15,20 On the one hand, it has a great clinical importance due to the opportunity to better assess the degree of myocardial damage in a number of pathological conditions, such as sepsis, pulmonary embolism (PE), inflammatory myocardial diseases, but on the other hand, it can make differential diagnosis more difficult and contribute to incorrect diagnoses. This is especially true in cases where clinicians excessively rely only on the results of patients' laboratory examinations. It is very important to understand that an increase in the concentration of cardiac troponins in biological fluids, in particular in blood serum, indicates reversible or irreversible damage to cardiomyocytes, but does not explain the etiopathogenesis of such damage, which may occur in a number of other pathological p -Abstract Truncated-

Expanding Functions or Causing Pathologies?

Focus on cardiac troponin complex: From gene expression to cardiomyopathy

Troponin through the looking-glass: emerging roles beyond regulation of striated muscle contraction

Hypertrophic Cardiomyopathy Mutations of Troponin Reveal Details of Striated Muscle Regulation

The Impact of Myosin Heavy Chain Isoforms on Contractile Behavior of the Heart

[Effects of Tumor Necrosis Factor Alpha on Expression of Phospholamban and Intracellular Calcium in Cardiomyocytes].

Structural dynamics of the intrinsically disordered linker region of cardiac troponin T

Early Divergence of the C-Terminal Variable Region of Troponin T Via a Pair of Mutually Exclusive Alternatively Spliced Exons Followed by a Selective Fixation in Vertebrate Heart

A comprehensive guide to genetic variants and post-translational modifications of cardiac troponin C

Myofilament Calcium Sensitivity: Consequences of the Effective Concentration of Troponin I

Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review)

Intranuclear Cardiac Troponin I Plays a Functional Role in Regulating Atp2a2 Expression in Cardiomyocytes

The Main Causes and Mechanisms of Increase in Cardiac Troponin Concentrations Other Than Acute Myocardial Infarction (Part 1): Physical Exertion, Inflammatory Heart Disease, Pulmonary Embolism, Renal Failure, Sepsis

Cardiac troponin I directly binds and inhibits mitochondrial ATP synthase with a noncanonical role in the post-ischemic heart

C-terminal troponin-I residues trap tropomyosin in the muscle thin filament blocked-state

Troponin structural dynamics in the native cardiac thin filament revealed by cryo electron microscopy

Clinical Biochemistry of Serum Troponin

Molecular dynamics provides new insights into the mechanism of calcium signal transduction and interdomain interactions in cardiac troponin

Myocardial injury, troponin release, and cardiomyocyte death in brief ischemia, failure, and ventricular remodeling

The transmission of mutation effects in a multiprotein machine: A comprehensive metadynamics study of the cardiac thin filament

Pathogenic TNNI1 variants disrupt sarcomere contractility resulting in hypo- and hypercontractile muscle disease